雙磷酸鹽類藥物使用對骨鬆骨折病人死亡率的影響－健保資料庫分析

Bisphosphonate and Mortality in Patients with Osteoporotic Fracture: An Analysis based on National Health Insurance Research Database

許育煊(Yu-Hsuan Hsu) ； 李佳純(Chia-Chun Li) ； 梁富文(Fu-Wen Liang) ； 張尹凡(Yin-Fan Chang) ； 徐之昇(Jason C. Hsu) ； 吳至行(Chih-Hsing Wu)

《台灣家庭醫學雜誌》 31卷3期 (2021/09) Pp. 199-213

https://doi.org/10.3966/168232812021093103004

摘要

目的：使用骨質疏鬆藥物可降低骨鬆骨折後死亡風險，而台灣相對缺乏本土的巨資料研究，尤其是雙磷酸鹽類藥物的研究更是不足。本研究旨在探討骨鬆骨折後有無使用雙磷酸鹽類藥物對死亡率之影響。方法：本研究納入2009至2017年全民健康保險資料庫之門診有骨質疏鬆症診斷且有住院骨折住院診斷新發個案，串聯死因統計檔，分析有無使用雙磷酸鹽類藥物對於全死因死亡的風險。結果：本研究總樣本為149,288人，存活者平均追蹤人年為4.96人年，死亡者為3.15人年。相較於無使用雙磷酸鹽類藥物者，使用雙磷酸鹽類藥物的死亡風險比為0.97 （95% CI 0.95-0.99）。而單獨使用口服alendronate／risedronate的死亡風險比為1.01（95% CI 0.99-1.03），針劑ibandronate為0.87（95% CI 0.81-0.93），針劑zoledronic acid則為0.74（95% CI 0.70-0.78）。在髖骨骨折或脊椎骨折的次分析皆有相似結果。結論：本研究發現骨鬆骨折個案使用雙磷酸鹽類藥物者之整體死亡風險顯著降低，尤其是針劑藥物。此研究結果應可供臨床實務及公共政策之參考。

關鍵字

骨質疏鬆症 ； 骨折 ； 死亡率 ； 雙磷酸鹽類藥物

並列摘要

Purpose: While pharmacological intervention does help reduce the risk of total mortality induced by osteoporotic fracture, few studies have been conducted to examine the impact of specific drugs, especially bisphosphonates, on osteoporotic fractures in Taiwan. Therefore, the study aimed to analyze the relationship between the use of bisphosphonates for osteoporotic fractures and resulting mortality. Methods: The National Health Insurance Research Database (NHIRD), together with the Cause of Death Data, provided by Health and Welfare Data Science Center was consulted for analysis on subjects hospitalized for osteoporotic fracture from 2009 to 2017 to study the connection between the use of bisphosphonates and mortality among patients with osteoporotic fracture. Results: A total of 149,288 valid participants were enrolled, and the mean follow-up personyears of the survivor and death were respectively 4.96 and 3.15. Compared with those who used no bisphosphonates, the mortality hazard ratio was 0.97 (95% confidence interval, CI 0.95-0.99) for patients receiving bisphosphonates, 1.01 (95% CI 0.99-1.03) for oral alendronate/risedronate, 0.87 (95% CI 0.81-0.93) for ibandronate by injection, and 0.74 (95% CI 0.70-0.78) for zoledronic acid in total fractures. Consistent results were found in subgroup-analysis of hip fractures or spine fractures. Conclusion: Use of bisphosphonates, especially through injection, appears to be significantly associated with reduced mortality in patients with osteoporotic fractures. The result of this study should be considered in clinical practice and public policy.

並列關鍵字

bisphosphonate ； fractures ； mortality ； osteoporosis

參考文獻

Yang NP, Deng CY, Chou YJ, et al: Estimated prevalence of osteoporosis from a Nationwide Health Insurance database in Taiwan. Health Policy 2006; 75: 329-337.

Bureau of Health Promotion DoH, ROC (Taiwan), Center for Evidence-Based Medicine TMU, Association TTO: Taiwan Osteoporosis Practice Guidelines. December 2012.

Wu CH, McCloskey EV, Lee JK, et al: Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region. J Clin Densitom 2014; 17: 150-155.

蕭正光、蔡克嵩：臺灣地區骨質疏鬆症之流行現況。國人骨質疏鬆症防治指引。臺北：行政院衛生署，1997：6-10。

中華民國骨質疏鬆症學會：2019台灣成人骨質疏鬆症防治之共識及指引（2020增修版）。2021年1月27日，取自http://www.toa1997.org.tw/download/files/2020台灣成人骨質疏鬆症防治之共識及指引-公告.pdf。